Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 2Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 38Radiotherapy 17Filgrastim 14Surgical Procedures, Operative 11Irinotecan 11Carmustine 10Carboplatin 10Radiation 9O(6)-benzylguanine 9Magnetic Resonance Spectroscopy 9Specimen Handling 7Granulocyte Colony-Stimulating Factor 7Flucytosine 7sargramostim 6Radiotherapy, Intensity-Modulated 5Peripheral Blood Stem Cell Transplantation 5Etoposide 5Erlotinib Hydrochloride 5Bevacizumab 5vocimagene amiretrorepvec 4Vorinostat 4Thiotepa 4Melphalan 4Lenalidomide 4IL13-PE38 4Genetic Therapy 4Cyclophosphamide 4Chemotherapy, Adjuvant 4Busulfan 4lonafarnib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Astrocytoma × Eflornithine × Clear all
NCT05879367 2025-06-25

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Orbus Therapeutics, Inc.

Phase 1 Recruiting
66 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡